Electra Therapeutics Reports Q3 2026 Results, $402.5 Million in Cash

Electra Therapeutics reported a third-quarter 2026 net loss of $23.9 million and ended September with $402.5 million in cash, cash equivalents and marketable securities. The company said its cash position is expected to fund planned operations into 2029. Its portfolio update included progress in cl…